Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (583)	7/10/1998 12:10:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 1906

Harold, Tomorrow's Science will have the paper on LGND's Neupogen mimic. Although the Science paper is on a mouse-specific compound, the SBH alliance in the Ligand Pipleline table at home.att.net or home.att.net would seem to indicate that a human version has been identified and is in pre-clinical testing. I have updated the G-CSF (Neupogen) table at home.att.net to include today's press releases, tomorrow's Science abstract and commentary, as well as abstracts to be presented next week, next month, and in October. I suspect that the news will get AMGN's attention. LGND has indicated that SBH was "gobbling up" LGND targets and Epogen, Neupogen and Leptin have already been announced (and more hematpoietic growth factors are being targeted). The technology can be applied to virtually any interleukin, interferon, or growth factor, so I suspect that tomorrow's paper will get the attention of the entire sector.